TippingPoint Biosciences Closes New Funding to Support Drug for Rare Pediatric Brain Tumor
SAN FRANCISCO, Sept. 4, 2024 /PRNewswire/ -- TippingPoint Biosciences, a therapeutic company focused on innovative drug discovery targeting the aberrant DNA in cancer cells, today announced pre-seed investment from the Pediatric Brain Tumor Foundation, Sontag Foundation, Yuvaan Tiwari Foundation, and BrightEdge, the impact investment and venture capital arm of the American Cancer Society.
The investments will support TippingPoint's breakthrough work to target Diffuse Intrinsic Pontine Glioma (DIPG), a rare pediatric brainstem tumor that is untreatable and terminal, usually within months of diagnosis. TippingPoint's novel drug discovery platform is the first to target disease-specific interfaces in DNA packaging networks in cancer cells, also known as chromatin states, without affecting healthy states. Current approaches to address DNA packaging dysfunction target single chromatin factors that have broad functions across both disease and healthy cells, which leads to unwanted toxicities. Because TippingPoint's platform is able to specifically target the unique chromatin interactions in disease, they have successfully applied their technology to target DIPG cancer cells in the laboratory, which cancer researchers regard as a significant breakthrough.
"We are committed to accelerating breakthrough treatments for DIPG and other fatal pediatric brain tumors," said Parvati Tiwari, President and Co-Founder of the Yuvaan Tiwari Foundation. "TippingPoint's innovative approach to targeting complex chromatin interactions offers real hope for new therapies. We're proud to back their efforts to transform the future of DIPG treatment."
"We are proud to support the work being done by Tipping Point to further the American Cancer Society's mission to end cancer as we know it for everyone, said Alice Pomponio, VP, Innovation & Impact Investing / Managing Director, BrightEdge. It has been a privilege to support their journey from the beginning to where they are today, and we look forward to seeing a DIPG treatment benefit people with cancer in the future."
"There will be no cure for DIPG without collaboration, and we're proud to come alongside other investors to back TippingPoint's novel search for new treatment pathways," said Pediatric Brain Tumor Foundation President and CEO Courtney Davies. "We believe their research focus promises to be transformative."
The Sontag Innovation Fund, building on the reputation of the Sontag Foundation as one of the largest private funders of brain tumor research in North America, is thrilled with being part of TippingPoint's efforts. "We are excited to help support TippingPoint and their effort to use an innovative screening platform to identify new potential therapeutic options for DIPG and other diseases" said Scott Davis, Managing Director of the Sontag Innovation Fund.
TippingPoint Bioscience's founder, Dr. Laura Hsieh, formerly a post-doctoral researcher in Dr. Geeta Narlikar's lab at the University of California San Francisco (UCSF), left the university to launch TippingPoint and accelerate the development of cancer therapeutics. TippingPoint raised its first investments in 2023, from early stage ventures like Mission BioCapital, ACS BrightEdge and SOSV's IndieBio, and won four golden or platinum ticket awards in pitch competitions sponsored by major pharmaceutical companies including ONO Pharma, Astellas, and Abbvie.
Dr. Hsieh and the TippingPoint Biosciences team are currently conducting hit-to-lead studies to develop a new class of molecules for DIPG that are highly specific to the disease. They are diligently working to increase the potency and selectivity of their molecules so they can test them in mouse models in the near term with an eye on reaching first-in-human studies for DIPG patients in 4 years.
"We are honored to receive these investments to further our drug development efforts for such a devastating disease like DIPG. In order to make significant breakthroughs in complex diseases like DIPG and really make a difference in patient lives, big bets need to be made on paradigm-shifting technologies like ours. The support in capital, expertise and networks with patient advocates and world-class researchers goes a long way for TippingPoint to continue development of much-needed therapeutics for DIPG and other complex diseases," said Dr. Laura Hsieh, CEO and Founder of TippingPoint Biosciences.
About TippingPoint Biosciences
TippingPoint Biosciences is an early-stage therapeutic company with a novel drug discovery platform to identify first-in-class drugs aimed at treating diseases related to dysfunctional DNA packaging (chromatin). TippingPoint Bio is the first to develop a screening platform to enable direct targeting of the defective chromatin in disease cells without affecting healthy cells. The platform can be applied to multiple disease areas like cancer, neurodegenerative diseases and developmental disorders. For more information, please visit www.tippingpointbiosciences.com.
About the Pediatric Brain Tumor Foundation
Since 1991, the Pediatric Brain Tumor Foundation has led the way in funding research into pediatric brain tumors, supporting families affected by this disease, and advocating for policies that help patients, survivors, and their loved ones. Dedicated wholly to addressing this rare disease and guided by the experiences of patients, survivors, their parents, and siblings, the Pediatric Brain Tumor Foundation meets families' needs along every step of their cancer journey. The foundation also funds and advocates for innovative projects that lead to vital discoveries, new clinical trials, and better treatments.
About The Sontag Innovation Fund
The Sontag Innovation Fund, a wholly-owned venture subsidiary of The Sontag Foundation, one of the largest private funders of brain cancer research in the United States, made the investment. The Sontag Innovation Fund invests in early stage and innovative technologies with the potential to drive cures and improve the quality of life or life expectancy for brain cancer patients. (www.sontagfoundation.org/innovation-fund/)
About the Yuvaan Tiwari Foundation
The Yuvaan Tiwari Foundation was established in 2021 by Parvati and Satya Tiwari to honor the legacy of their son Yuvaan (Yuvi). At age two, Yuvi was diagnosed with an aggressive and fatal brain tumor called diffuse midline glioma (DMG). Yuvi fought DMG bravely for seven months. The Yuvaan Tiwari Foundation accelerates high-impact research to find a cure for DMGs and other fatal pediatric brain cancers, while supporting patients and families along their journey. (www.ytfoundation.org)
SOURCE TippingPoint Biosciences
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article